NCT06319300 Artificial Intelligence-assisted Insulin System in Type 2 Diabetes in General Wards

Trial Parameters

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Our study was a single-blind, randomised, controlled, multicentre study. The study was planned to include 140 patients admitted to the general ward for subcutaneous insulin therapy, who were randomly divided into two groups in the ratio of 1:1, one group with an artificial intelligence assisted insulin dosimetry system to adjust the insulin dose to control their blood glucose, and the other group with a physician instituted insulin dosimetry adjustments to control their blood glucose. The effectiveness and safety of the system was confirmed by comparing the glycaemic control and risk of adverse events between the two groups.

Eligibility Criteria

Inclusion Criteria: * Diagnosis of type 2 diabetes mellitus \> 3 months * Age≥18 years old * Receiving glucose-lowering therapy for at least 90 days * Blood glucose:7.8-22.2 mmol/L * Length of proposed hospitalisation ≥5 days Exclusion Criteria: * Type 1 diabetes mellitus, other special types of diabetes mellitus. * BG\>22.2 mmol/L, or acute complications of diabetes, such as diabetic ketoacidosis, diabetic hyperosmolar state. * History of severe or repeated hypoglycaemia * BMI≥45 kg/m2 * Pregnant and lactating women * Clinically relevant liver disease (established cirrhosis and portal hypertension); * Presence of severe renal disease (serum creatinine ≥3.0 mg/dL or estimated glomerular filtration rate \<30 ml/min/1.73 m2); * Severe cardiac insufficiency; * Patients on cortisol-based hormone therapy (equivalent to a prednisone dose \>5 mg/day); * Psychiatric abnormalities or impaired cognitive function; * Patients with severe oedema, infection, or peripheral blood circulation disorder;

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.